Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.
Recent Videos
Related Content
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Article
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
